Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 258 participants.
Also called NCT04196231
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 258 participants
- Registry
-
NCT04196231
-
- Other papers using this trial's data
- BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes
- Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT04196231. Randomized; no masking; primary purpose treatment. Start 2019-11-27 (actual); primary completion 2020-09-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
- Acronym
- BEYOND
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- IDegLira
- Intervention (Drug)
- IGlarLixi
- Intervention (Drug)
- Insulin/Canaglifozin
- Intervention (Drug)
- Insulin/Dapaglifozin
- Intervention (Drug)
- Insulin/Empaglifozin
- Intervention (Drug)
- Basal Bolus
- Lead sponsor
- University of Campania Luigi Vanvitelli
Record details
- Record id
cardio:ct-nct04196231- Content hash
0c20d2c2fa92d6870b838e92ac0d8afc0bd49a1d8aabd58a741d61e025914204